APV Introduces 'Combi MP' Pilot to Advance Functional Whey Protein Innovation
Trials are underway at SPX FLOW's Denmark Innovation Center, with new customer rentals available in
Already in high demand, the company's "Combi" design allows producers to test recipes using two APV microparticulation technologies, the LeanCreme™ and the Cavimaster™, from one shared platform. This design offers flexibility and efficiency in application trials.
See the new line here: https://www.spxflow.com/assets/WebJPG1000px/combi-mp.jpg
"This innovation gives our customers a competitive edge," said
Whey protein has become one of the most sought-after dairy ingredients in the food and nutrition industry, valued for its health benefits and versatility in formulations such as ready-to-drink coffees, desserts and fermented dairy products. At a modest flow rate of 150 liters/hour from this line, customers can perform tests using limited product quantities while gathering valuable process data to guide full-scale production.
Leading global dairy brands are investing heavily in microparticulation to enhance their protein-based product lines. SPX FLOW's combination of application expertise and pilot-scale testing units sets it ahead of industry peers in meeting this demand.
To learn more about the two technologies independently, explore the LeanCreme™ technology here: https://www.spxflow.com/apv/products/leancreme-systems, and the Cavimaster™ technology here: https://www.spxflow.com/apv/products/cavimaster-systems.
About SPX FLOW, Inc.
Based in
Media Contact:
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/apv-introduces-combi-mp-pilot-to-advance-functional-whey-protein-innovation-302594791.html
SOURCE SPX FLOW, INC.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EZ Texting Launches AI-Powered RCS Business Messaging, Delivering 7x Higher Engagement to 230,000+ Small Businesses
- Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
- A2GOLD INTERSECTS 20.96 G/T AUEQ OVER 1.5 METRES (5.24% ANTIMONY AND 0.52 G/T GOLD); RETURNS 209.4 G/T SILVER OVER 10.7 METRES FROM SURFACE AT TAYLOR
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share